TR200103184T2 - MEK enzimlerinin inhibitrleri olarak kinolin trevleri - Google Patents
MEK enzimlerinin inhibitrleri olarak kinolin trevleriInfo
- Publication number
- TR200103184T2 TR200103184T2 TR2001/03184T TR200103184T TR200103184T2 TR 200103184 T2 TR200103184 T2 TR 200103184T2 TR 2001/03184 T TR2001/03184 T TR 2001/03184T TR 200103184 T TR200103184 T TR 200103184T TR 200103184 T2 TR200103184 T2 TR 200103184T2
- Authority
- TR
- Turkey
- Prior art keywords
- alkyl
- group
- optionally
- carbon
- various
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Bir ilaç olarak kullan m için formül (I)'e sahip bir bileçik veya bunun farmasötik aç dan kabul edilebilir tuzu olup; burada: n, 0-1 dir; Y, -NH-, -O-, -S- veya -NR7-den seçilir, burada R7, 1-6 karbon atomlu alkildir; R5, klor veya bromdur; Y, -NH-, -O-, -S- veya -NR7- den seçilir, burada R7; -6 karbon atomlu alkildir, R6; çeçitli sübstitüentlerle sübstitüe edilmiç olabilen tan mlanm ç bir halkal gruptur veya R6; bir -R8-X-R9 grubudur. Bu bileçikler, MEK enzimlerinin inhibe edilmesine özellikle yararl d rlar.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9910579.3A GB9910579D0 (en) | 1999-05-08 | 1999-05-08 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200103184T2 true TR200103184T2 (tr) | 2002-03-21 |
Family
ID=10852988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/03184T TR200103184T2 (tr) | 1999-05-08 | 2000-05-03 | MEK enzimlerinin inhibitrleri olarak kinolin trevleri |
Country Status (17)
Country | Link |
---|---|
US (1) | US6809106B1 (tr) |
EP (1) | EP1178966B1 (tr) |
JP (1) | JP2002544195A (tr) |
KR (1) | KR20010110810A (tr) |
CN (1) | CN1352635A (tr) |
AT (1) | ATE252561T1 (tr) |
AU (1) | AU4589700A (tr) |
BR (1) | BR0010324A (tr) |
CA (1) | CA2370838A1 (tr) |
DE (1) | DE60006099T2 (tr) |
GB (1) | GB9910579D0 (tr) |
IL (1) | IL146326A0 (tr) |
NO (1) | NO20015446L (tr) |
NZ (1) | NZ514814A (tr) |
TR (1) | TR200103184T2 (tr) |
WO (1) | WO2000068200A1 (tr) |
ZA (1) | ZA200108965B (tr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
GB0225579D0 (en) * | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
ES2389258T3 (es) * | 2003-06-17 | 2012-10-24 | Millennium Pharmaceuticals, Inc. | Composiciones y métodos para inhibir TGF-s |
JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス, インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
ES2349066T3 (es) * | 2006-09-15 | 2010-12-22 | Pfizer Inc. | Compuestos de piridilmetilbiciclocarboxamida sustituida. |
CN101679357A (zh) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
CA2935804A1 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
KR20180086187A (ko) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE317376B (tr) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
US4743601A (en) * | 1987-07-13 | 1988-05-10 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydro-1,4-oxazino(2,3-C)quinolines |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0597003A1 (en) | 1991-08-02 | 1994-05-18 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ATE300521T1 (de) | 1996-09-25 | 2005-08-15 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
JP4548642B2 (ja) | 1998-09-29 | 2010-09-22 | アメリカン・サイアナミド・カンパニー | プロテインチロシンキナーゼインヒビターとしての置換3−シアノキノリン |
ES2457396T3 (es) | 1998-09-29 | 2014-04-25 | Wyeth Holdings Llc | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas |
-
1999
- 1999-05-08 GB GBGB9910579.3A patent/GB9910579D0/en not_active Ceased
-
2000
- 2000-05-03 IL IL14632600A patent/IL146326A0/xx unknown
- 2000-05-03 AT AT00927497T patent/ATE252561T1/de not_active IP Right Cessation
- 2000-05-03 BR BR0010324-1A patent/BR0010324A/pt not_active IP Right Cessation
- 2000-05-03 AU AU45897/00A patent/AU4589700A/en not_active Abandoned
- 2000-05-03 NZ NZ514814A patent/NZ514814A/en unknown
- 2000-05-03 DE DE60006099T patent/DE60006099T2/de not_active Expired - Fee Related
- 2000-05-03 KR KR1020017014190A patent/KR20010110810A/ko not_active Application Discontinuation
- 2000-05-03 CN CN00807282A patent/CN1352635A/zh active Pending
- 2000-05-03 TR TR2001/03184T patent/TR200103184T2/tr unknown
- 2000-05-03 US US09/959,005 patent/US6809106B1/en not_active Expired - Fee Related
- 2000-05-03 JP JP2000617180A patent/JP2002544195A/ja active Pending
- 2000-05-03 EP EP00927497A patent/EP1178966B1/en not_active Expired - Lifetime
- 2000-05-03 WO PCT/GB2000/001707 patent/WO2000068200A1/en not_active Application Discontinuation
- 2000-05-03 CA CA002370838A patent/CA2370838A1/en not_active Abandoned
-
2001
- 2001-10-30 ZA ZA200108965A patent/ZA200108965B/en unknown
- 2001-11-07 NO NO20015446A patent/NO20015446L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010110810A (ko) | 2001-12-13 |
CA2370838A1 (en) | 2000-11-16 |
AU4589700A (en) | 2000-11-21 |
NO20015446L (no) | 2001-12-12 |
GB9910579D0 (en) | 1999-07-07 |
NO20015446D0 (no) | 2001-11-07 |
EP1178966B1 (en) | 2003-10-22 |
US6809106B1 (en) | 2004-10-26 |
NZ514814A (en) | 2003-10-31 |
BR0010324A (pt) | 2002-01-08 |
IL146326A0 (en) | 2002-07-25 |
DE60006099T2 (de) | 2004-07-08 |
CN1352635A (zh) | 2002-06-05 |
ATE252561T1 (de) | 2003-11-15 |
EP1178966A1 (en) | 2002-02-13 |
WO2000068200A1 (en) | 2000-11-16 |
JP2002544195A (ja) | 2002-12-24 |
ZA200108965B (en) | 2003-01-30 |
DE60006099D1 (de) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200103184T2 (tr) | MEK enzimlerinin inhibitrleri olarak kinolin trevleri | |
NO20015447L (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
NO20015448D0 (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
HUP0104816A2 (hu) | 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra | |
PE20050371A1 (es) | Inhibidores de la caspasa conteniendo anillo isoxazolinico | |
RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
MY104376A (en) | N-imidazolyl deravatives of bicyclic compounds and process for their preparation. | |
HUP9903836A2 (hu) | Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására | |
IL98681A (en) | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives | |
DE60239170D1 (de) | Bicyclische Verbindungen | |
FR2491470B1 (tr) | ||
MX9708422A (es) | Esteres de carbapenemas. | |
ATE14314T1 (de) | 7-beta-(ketooximinoacylamido)-ceph-3-em-4carbons|urederivate, verfahren zur herstellung derselben und diese enthaltende arzneimittel. | |
ES8800663A1 (es) | Procedimiento para preparar compuestos arilsulfonicos. | |
KR910021376A (ko) | 6-치환된-헥사하이드로벤즈[cd]인돌 | |
ATE18042T1 (de) | Semicarbazide, ihre herstellung und verwendung. |